Hypoxia Responsive Drug Delivery Systems in Tumor Therapy

被引：37

作者：

Alimoradi, Houman ^{[1
]}

Matikonda, Siddharth S. ^{[2
]}

Gamble, Allan B. ^{[2
]}

Giles, Gregory I. ^{[1
]}

Greish, Khaled ^{[1
,3
]}

机构：

[1] Univ Otago, Dept Pharmacol & Toxicol, Adams Bldg,3rd Floor,18 Frederick St, Dunedin 9016, New Zealand

[2] Univ Otago, Sch Pharm, Dunedin 9016, New Zealand

[3] Arabian Gulf Univ, Aljawhara Ctr Mol Med, Manama, Bahrain

来源：

CURRENT PHARMACEUTICAL DESIGN | 2016年 / 22卷 / 19期

关键词：

Tumor hypoxia; delivery systems; nitroimidazole; azobenzene; metal complexes; oxygen carriers; FLUOSOL-DA; 20-PERCENT; SOFT-TISSUE SARCOMAS; GENE-THERAPY; SALMONELLA-TYPHIMURIUM; CYTOSINE DEAMINASE; VASCULAR-PERMEABILITY; EXTRACELLULAR-MATRIX; FLUORESCENT-PROBES; BLOOD SUBSTITUTES; CLINICAL-TRIAL;

D O I：

10.2174/1381612822666160217130049

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Hypoxia is a common characteristic of solid tumors. It is mainly determined by low levels of oxygen resulting from imperfect vascular networks supplying most tumors. In an attempt to improve the present chemotherapeutic treatment and reduce associated side effects, several prodrug strategies have been introduced to achieve hypoxia-specific delivery of cytotoxic anticancer agents. With the advances in nanotechnology, novel delivery systems activated by the consequent outcomes of hypoxia have been developed. However, developing hypoxia responsive drug delivery systems (which only depend on low oxygen levels) is currently naive. This review discusses four main hypoxia responsive delivery systems: polymeric based drug delivery systems, oxygen delivery systems combined with radiotherapy and chemotherapy, anaerobic bacteria which are used for delivery of genes to express anticancer proteins such as tumor necrosis alpha (TNF-alpha) and hypoxia-inducible transcription factors 1 alpha (HIF1 alpha) responsive gene delivery systems.

引用

页码：2808 / 2820

页数：13

共 130 条

[1]

Avendaño C, 2008, MEDICINAL CHEMISTRY OF ANTICANCER DRUGS, P417, DOI 10.1016/B978-0-444-52824-7.00013-5

[2] Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as tool for anti-tumor treatment [J].

Barbé, S ;

Van Mellaert, L ;

Theys, J ;

Geukens, N ;

Lammertyn, E ;

Lambin, P ;

Anné, J .

FEMS MICROBIOLOGY LETTERS, 2005, 246 (01) :67-73

[3]

Batchelder R., 1996, BRIT J CANC SUPPLEME, V27, P52

[4] Fe-S proteins in sensing and regulatory functions [J].

Beinert, H ;

Kiley, PJ .

CURRENT OPINION IN CHEMICAL BIOLOGY, 1999, 3 (02) :152-157

[5] HYPOXIA AND METABOLISM SERIES - TIMELINE The impact of O2 availability on human cancer [J].

Bertout, Jessica A. ;

Patel, Shetal A. ;

Simon, M. Celeste .

NATURE REVIEWS CANCER, 2008, 8 (12) :967-975

[6] The role of hypoxia in inflammatory disease [J].

Biddlestone, John ;

Bandarra, Daniel ;

Rocha, Sonia .

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2015, 35 (04) :859-869

[7]

Brizel DM, 1996, CANCER RES, V56, P941

[8] PATTERNS AND VARIABILITY OF TUMOR OXYGENATION IN HUMAN SOFT-TISSUE SARCOMAS, CERVICAL CARCINOMAS, AND LYMPH-NODE METASTASES [J].

BRIZEL, DM ;

ROSNER, GL ;

PROSNITZ, LR ;

DEWHIRST, MW .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (04) :1121-1125

[9] Tumor hypoxia in cancer therapy [J].

Brown, J. Martin .

OXYGEN BIOLOGY AND HYPOXIA, 2007, 435 :297-+

[10]

Brown JM, 1999, CANCER RES, V59, P1391

← 1 2 3 4 5 6 7 8 9 10 →